SecurityBLCM / Bellicum Pharmaceuticals, Inc. (079481107)
President and CEOFair Richard A.
IndustryPharmaceutical Preparations
Institutional Owners98
Institutional Shares20,299,203 - 47.35%
Common Shares Outstanding42,873,045 shares (as of 2018-03-31)
Institutional Value$ 341,629,000 USD

Institutional Stock Ownership and Shareholders()

BLCM / Bellicum Pharmaceuticals, Inc. Institutional Ownership

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has 98 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 20,299,203 shares. Largest shareholders include Baker Brothers Advisors LP, JP Morgan Chase & Co, BlackRock Inc., FMR LLC / Fidelity, Vanguard Group Inc, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., State Street Corp, Ascend Capital, Llc, and Morgan Stanley.
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/blcm"><img src="https://images.fintel.io/us-blcm-so.png" alt="BLCM / Bellicum Pharmaceuticals, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 90,000 54,500 -39.44 757 358 -52.71
2018-05-15 13F-HR UBS Group AG 5,280 5,015 -5.02 44 33 -25.00
2018-05-15 13F-HR Advisor Group, Inc. 5,900 6,800 15.25 49 45 -8.16
2018-02-09 13F-HR RidgeWorth Capital Management LLC 40,822 343
2018-05-14 13F-HR Tekla Capital Management LLC 60,000 60,000 0.00 505 394 -21.98
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 396,384 513,443 29.53 7,888 6,993 -11.35
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 290,731 152,280 -47.62 2,445 999 -59.14
2018-05-15 13F-HR BlueCrest Capital Management Ltd 0 11,447 0 75
2018-05-15 13F-HR Voya Investment Management LLC 11,319 11,319 0.00 95 74 -22.11
2018-05-15 13F-HR Baker Brothers Advisors LP 5,032,313 4,151,578 -17.50 42,322 27,234 -35.65
2018-05-11 13F-HR MCDANIEL TERRY & CO 23,900 13,900 -41.84 201 91 -54.73
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 148,860 168,484 13.18 1,252 1,105 -11.74
2018-05-15 13F-HR Squarepoint Ops LLC 0 10,893 0 71
2018-04-27 13F-HR HARVEY CAPITAL MANAGEMENT INC 31,200 31,200 0.00 262 204 -22.14
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 2,385 2,385 0.00 20 16 -20.00
2018-06-14 13F-HR/A Dynamic Technology Lab Private Ltd 0 25,860 0 170
2018-05-14 13F-HR Virtu Financial LLC 69,039 0 -100.00 581 0 -100.00
2018-05-15 13F-HR Boxer Capital, LLC 350,000 2,296
2018-05-09 13F-HR NORTHERN TRUST CORP 338,693 313,198 -7.53 2,848 2,054 -27.88
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 128,846 152,668 18.49 1,084 1,002 -7.56
2018-05-01 13F-HR Clear Harbor Asset Management, LLC 10,950 0 -100.00 92 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 7,726 7,423 -3.92 154 101 -34.42
2018-05-04 13F-HR D.A. DAVIDSON & CO. 40,700 0 -100.00 342 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 49,500 325
2018-05-15 13F-HR HighTower Advisors, LLC 38,050 57,110 50.09 316 375 18.67
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 4,058 7,262 78.96 34 47 38.24
2018-05-11 13F-HR X-square Capital, Llc 64,614 70,814 9.60 544 464 -14.71
2018-05-15 13F-HR Bank of New York Mellon Corp 108,518 109,440 0.85 912 718 -21.27
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 24,400 22,500 -7.79 205 148 -27.80
2018-05-04 13F-HR Asset Planning Services, Ltd. 350 350 0.00 3 2 -33.33
2018-05-10 13F-HR JP Morgan Chase & Co 2,339,068 2,863,044 22.40 19,672 18,782 -4.52
2018-04-26 13F-HR SIMPLEX TRADING, LLC 4,823 7,750 60.69 40 50 25.00
2018-05-02 13F-HR Daiwa Securities Group Inc. 184 1
2018-05-15 13F-HR VANGUARD GROUP INC 1,361,357 1,349,300 -0.89 11,448 8,851 -22.69
2018-05-15 13F-HR BARCLAYS PLC 20,746 13,201 -36.37 174 86 -50.57
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 23,000 13,400 -41.74 193 88 -54.40
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 510 610 19.61 4 5 25.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 110,028 164,471 49.48 924 1,077 16.56
2018-07-16 13F-HR FRANKLIN STREET ADVISORS INC /NC 49,685 50,545 1.73 326 373 14.42
2018-05-15 13F-HR Man Group plc 63,500 417
2018-05-15 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 59,190 0 -100.00 498 0 -100.00
2018-05-14 13F-HR Prosight Management, LP 301,349 106,050 -64.81 2,534 696 -72.53
2018-05-14 13F-HR ProShare Advisors LLC 21,949 18,850 -14.12 185 124 -32.97
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 13,400 88
2018-04-20 13F-HR Steward Partners Investment Advisory, Llc 880 880 0.00 7 5 -28.57
2018-02-14 13F-HR NUMERIC INVESTORS LLC 29,462 11,862 -59.74 340 100 -70.59
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 23,157 22,661 -2.14 195 148 -24.10
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 0 11,755 0 77
2018-05-14 13F-HR UBS ASSET MANAGEMENT AMERICAS INC 0 23,200 0 152,192
2018-05-14 13F-HR MORGAN STANLEY 253,078 362,167 43.10 2,129 2,377 11.65
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 159 158 -0.63 61 34 -44.26
2018-05-14 13F-HR Renaissance Technologies LLC 0 105,200 0 690
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 224,418 227,502 1.37 1,887 1,492 -20.93
2018-05-15 13F-HR BALYASNY ASSET MANAGEMENT LLC 0 20,076 0 132
2018-05-11 13F-HR Russell Investments Group, Ltd. 10,100 0 -100.00 85 0 -100.00
2018-05-11 13F-HR Cutler Group LP Call 4,300 0 -100.00 3 0 -100.00
2018-04-18 13F-HR Creative Planning 155,547 154,547 -0.64 1,308 1,014 -22.48
2017-02-10 13F-HR BlackRock Group LTD 6,973 7,834 12.35 139 107 -23.02
2018-05-02 13F-HR WASATCH ADVISORS INC 0 83,649 0 549
2018-05-17 13F-HR Legal & General Group Plc 6,948 5,235 -24.65 58 34 -41.38
2017-08-14 13F-HR NUMERIC INVESTORS LLC 0 97,380 0 1,137
2018-05-14 13F-HR ASCEND CAPITAL, LLC 400,994 2,630
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 18,303 17,369 -5.10 154 114 -25.97
2018-04-17 13F-HR BENJAMIN F. EDWARDS & COMPANY, INC. 200 0 -100.00 2 0 -100.00
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 12,358 18,888 52.84 104 123 18.27
2018-04-13 13F-HR Cwm Advisors, Llc 112 0 -100.00 1 0 -100.00
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 42,267 40,515 -4.15 355 266 -25.07
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 2,644 1,807 -31.66 22 12 -45.45
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 42,467 35,967 -15.31 357 236 -33.89
2018-07-09 13F-HR Berson & Corrado Investment Advisors, LLC 75,722 78,945 4.26 497 582 17.10
2018-05-11 13F-HR Cutler Group LP 8,378 3,400 -59.42 70 22 -68.57
2018-05-15 13F-HR CREDIT SUISSE AG/ 13,753 16,145 17.39 116 106 -8.62
2018-05-08 13F-HR US BANCORP \DE\ 1,000 1,000 0.00 8 7 -12.50
2018-05-15 13F-HR DAFNA Capital Management LLC 20,000 0 -100.00 168 0 -100.00
2018-05-11 13F-HR CITADEL ADVISORS LLC Put 24,100 158
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 124,260 245,868 97.87 1,045 1,613 54.35
2018-04-20 13F-HR Seacrest Wealth Management, Llc 1,050 450 -57.14 9 3 -66.67
2018-05-14 13F-HR TEACHERS ADVISORS INC 83,921 84,160 0.28 706 552 -21.81
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 12,600 12,300 -2.38 106 81 -23.58
2018-04-26 13F-HR Winslow, Evans & Crocker, Inc. 130 130 0.00 1,094 854 -21.94
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 106,189 128,524 21.03 894 844 -5.59
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 85 1
2018-05-14 13F-HR Vident Investment Advisory, LLC 150,426 205,255 36.45 1,265 1,835 45.06
2018-05-15 13F-HR KEYBANK NATIONAL ASSOCIATION/OH 15,061 99
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 283 2
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 140,300 150,800 7.48 1,180 989 -16.19
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 64,230 40,846 -36.41 541 268 -50.46
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 4,116 0 -100.00 35 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 2,314,166 2,263,186 -2.20 19,462 14,847 -23.71
2018-05-15 13F-HR ELLINGTON MANAGEMENT GROUP LLC 26,400 58,200 120.45 222 382 72.07
2017-02-10 13F-HR BlackRock Fund Advisors 945,216 1,057,512 11.88 18,810 14,403 -23.43
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Put 30,300 24,100 -20.46 255 158 -38.04
2017-02-10 13F-HR BlackRock Investment Management, LLC 82,628 82,959 0.40 1,644 1,130 -31.27
2018-05-23 13F-HR/A Allianz Asset Management AG 18,816 0 -100.00 158 0 -100.00
2018-05-11 13F-HR Compagnie Odier SCA 1,500 1,500 0.00 13 10 -23.08
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 13,970 0 -100.00 118 0 -100.00
2018-05-11 13F-HR Cutler Group LP Put 1,200 0 -100.00 3 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 6,212 6,483 4.36 52,243 42,528 -18.60
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 33,200 33,200 0.00 279 218 -21.86
2018-05-02 13F-HR RHUMBLINE ADVISERS 25,553 24,778 -3.03 215 163 -24.19
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 12,300 142
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 169 117 -30.77 21 2 -90.48
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 28,000 28,000 0.00 235 184 -21.70
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 43,146 41,996 -2.67 363 275 -24.24
2018-05-07 13F-HR MUFG Americas Holdings Corp 93 0 -100.00 1 0 -100.00
2018-05-15 13F-HR TUDOR INVESTMENT CORP ET AL 0 11,153 0 73
2018-05-03 13F-HR Zurcher Kantonalbank (Zurich Cantonalbank) 16,370 6,831 -58.27 138 45 -67.39
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 10,182 15,984 56.98 86 105 22.09
2018-05-11 13F-HR CITADEL ADVISORS LLC 181,723 1,192
2018-05-15 13F-HR LPL Financial LLC 16,626 17,026 2.41 140 112 -20.00
2018-05-08 13F-HR Pacific Center for Financial Services 200 200 0.00 2 1 -50.00
2018-05-04 13F-HR Swiss National Bank 44,300 44,300 0.00 373 291 -21.98
2018-05-15 13F-HR HighTower Advisors, LLC Call 5,500 0 -100.00 1 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 96,444 181,723 88.42 811 1,192 46.98
2018-05-14 13F-HR FMR LLC / Fidelity 2,629,542 1,994,672 -24.14 22,114 13,085 -40.83
2018-05-10 13F-HR Myda Advisors Llc 14,073 0 -100.00 118 0 -100.00
2018-05-15 13F-HR A.R.T. Advisors, LLC 0 88,012 0 577
2018-05-15 13F-HR Jefferies Group LLC 10,717 12,326 15.01 90 81 -10.00
2018-05-15 13F-HR STATE STREET CORP 438,277 450,332 2.75 3,689 2,956 -19.87
2018-05-15 13F-HR Endurant Capital Management LP 0 144,300 0 947
2018-05-08 13F-HR THRIVENT FINANCIAL FOR LUTHERANS 10,000 0 -100.00 84 0 -100.00
2018-04-30 13F-HR TCI Wealth Advisors, Inc. 500 400 -20.00 4 3 -25.00
2018-05-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 155,433 0 -100.00 1,307 0 -100.00
2018-05-03 13F-HR Trexquant Investment LP 24,810 0 -100.00 209 0 -100.00
2018-05-01 13F-HR Plante Moran Financial Advisors, LLC 350 350 0.00 3 2 -33.33
2018-05-07 13F-HR STATE OF WISCONSIN INVESTMENT BOARD 20,000 20,000 0.00 168 131 -22.02
2018-05-11 13F-HR CITIGROUP INC 232 11,768 4,972.41 2 77 3,750.00
2018-05-11 13F-HR KNOTT DAVID M 59,984 67,653 12.79 504 444 -11.90
2017-07-28 13F-HR RONALD BLUE & CO LLC 10,000 117
BLCM: Bellicum Pharmaceuticals Analysis and Research Report

2018-02-26 - Asif

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. Bellicum Pharmaceuticals is using its proprietary Chemical Induction of Dimerization, or CID technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating its CID platform, its product candidates may offer better safety and efficacy outcomes than are seen with current cellular immunotherapies. Bellicum Pharmaceuticals is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, chimeric antigen receptor T cell therapy, or CAR T, and T cell receptors, or TCRs. HSCT, also known as bone marrow transplanta...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

43m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Biotech: Take It On The Run

2018-07-05 seekingalpha
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making. (50-6)

Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

2018-06-20 biospace
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight. (310-4)

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

2018-05-31 seekingalpha
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme. (666-4)

The Kite Killer - TapImmune And Marker Merger Challenges Gilead

2018-05-30 seekingalpha
Gilead must address 95% grade 3 SAE’s with astrategic license or acquisition of a galectin blocker. (246-6)

The Kite Killer - TapImmune And Marker Merger Challenge Gilead

2018-05-30 seekingalpha
Gilead must address 95% grade 3 SAE’s with astrategic license or acquisition of a galectin blocker. (246-2)

CUSIP: 079481107